Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.
Biotechnology company Our lead asset, IMCIVREE® (setmelanotide), FDA-approved in 2020, is a precision medicine designed to treat severe obesity caused by an impairment of a pathway in the hypothalamus called the MC4R pathway.
Rhythm became a publicly traded company in 2017. Now, we have grown to more than 250 employees in North America and Europe. With a robust clinical trials program, we remain poised for even more growth in the near future. As we continue to grow, the one thing that will never change is our commitment to patients. Learn more about how Rhythm is changing how rare genetic disorders of obesity are diagnosed and treated.
Don't forget that the most detailed information about Rhythm Pharmaceuticals in Boston you can always get on the official web-site, in the company's office or by calling by phone ↓
yes
no
Thank you for your rating! Other users will thank you for it!
Write to the company
